Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne, Victoria, 3051
Australia

Notice of release of securities from Mandatory Escrow

Melbourne (Australia) – 29 October 2019. Pursuant to ASX Listing Rule 3.10A, Telix Pharmaceuticals Limited (ASX.TLX) ("**Telix**", the "**Company**") advises that the following securities which were classed as restricted securities and subject to ASX-imposed mandatory escrow at Listing are due be released from mandatory escrow on 15 November 2019.

Number	**Security type**
67,556,748	Ordinary shares
2,310,165	Options expiring 14 October 2021 (TLXO001)

An application for quotation of the ordinary shares (only) will be made on 15 November 2019 (Appendix 3B).

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com